Prostate cancer sufferers given hope with promising new drugs.
Several innovative pipeline treatments forecast to make a significant impact
As the US enters Prostate Health Month, leading independent analyst Datamonitor Healthcare has highlighted a number of promising new drugs in the pipeline with the potential to combat the increasing number of prostate cancer cases.
With the number of new patients in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) expected to increase by 20,000 to 600,000 in 2014, news of innovative drugs in the pipeline is particularly encouraging.
Johnson & Johnson’s oral drug Zytiga has already seen global sales figures for H1 2013 hit $739m and is expected to be a blockbuster drug this year, with estimated global sales reaching over $1bn. Other promising drugs include Medivation/Astellas’s Xtandi and Bayer’s radioactive drug Xofigo, which has recently been approved in the US and is also expected to gain approval in the EU in late 2013.
Prostate cancer awareness month in the US runs throughout September to raise awareness of the disease and encourage donations to prostate cancer charities.
Dr Joe Hedden, senior analyst at Datamonitor Healthcare, said: “Although the at-risk population of prostate cancer is increasing, it’s very positive to see a number of different drugs in the pipeline and we are expecting them to make a big impact in the market, particularly Zytiga.”
“It’s estimated that the total combined sales of prostate cancer drugs across the US, Japan, and the five major EU markets will reach $6.6bn by 2021, after increasing by $2.2bn since 2012 at a compound annual growth rate of 4.5%.”
About Datamonitor Healthcare…
Datamonitor Healthcare is the leading independent source of expert research across key pharmaceutical and biotechnology sectors. Our event-sensitive analysis evolves alongside the market to provide the most timely and representative market insight, supported by robust sources and methodologies that validate forecasts and assumptions. Rely on our global team of expert analysts, journalists and thought leaders to help you monitor and respond to spontaneous and disruptive industry developments.
For more information on this research, please Contact Us